[{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/","commit":"3b662d41c0","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for the last approved products without one","file":"src/data/spikes/breast-her2-positive.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20rezetecan\" }]"}]},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/","commit":"f8e98e6f47","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: HR+/HER2- and HER2+ breast cancer to TNBC depth (structured trial outcomes, dosing, toxicity, regulatory events)","file":"src/data/spikes/breast-her2-positive.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"code"},{"field":"modality"},{"field":"status"},{"field":"payload"},{"field":"linker"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"regulatoryEvents"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"}]}]